Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Related Articles by Review for PubMed (Select 12366426)

1.

Angiokeratoma corporis diffusum in a Spanish patient with aspartylglucosaminuria.

Vargas-Díez E, Chabás A, Coll MJ, Sánchez-Pérez J, García-Díez A, Fernández-Herrera JM.

Br J Dermatol. 2002 Oct;147(4):760-4. Review.

PMID:
12366426
2.
3.

Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.

Ikonen E, Peltonen L.

Hum Mutat. 1992;1(5):361-5. Review.

PMID:
1301945
4.

[Lysosomal storage diseases with angiokeratoma corporis diffusum].

Kanzaki T.

Nihon Rinsho. 1995 Dec;53(12):3062-7. Review. Japanese.

PMID:
8577059
5.

Angiokeratoma corporis diffusum in a patient with no recognizable enzyme abnormalities.

Kelly B, Kelly E.

Arch Dermatol. 2006 May;142(5):615-8. Review.

PMID:
16702499
6.

Angiokeratoma corporis diffusum in human beta-mannosidosis: Report of a new case and a novel mutation.

Molho-Pessach V, Bargal R, Abramowitz Y, Doviner V, Ingber A, Raas-Rothschild A, Ne'eman Z, Zeigler M, Zlotogorski A.

J Am Acad Dermatol. 2007 Sep;57(3):407-12. Epub 2007 Apr 8. Review.

PMID:
17420068
7.

Aspartylglycosaminuria: biochemistry and molecular biology.

Aronson NN Jr.

Biochim Biophys Acta. 1999 Oct 8;1455(2-3):139-54. Review.

8.

Angiokeratoma corporis diffusum: the evolution of a disease entity.

Taaffe A.

Postgrad Med J. 1977 Feb;53(616):78-81. Review.

9.

Aspartylglycosaminuria: an inborn error of glycoprotein catabolism.

Maury CP.

J Inherit Metab Dis. 1982;5(4):192-6. Review.

PMID:
6820440
10.

Fabry disease: recognition and management of cutaneous manifestations.

Möhrenschlager M, Braun-Falco M, Ring J, Abeck D.

Am J Clin Dermatol. 2003;4(3):189-96. Review.

PMID:
12627994
11.

Lysosomal storage diseases in adults.

Rapola J.

Pathol Res Pract. 1994 Sep;190(8):759-66. Review.

PMID:
7831151
12.

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D.

Health Technol Assess. 2006 Jun;10(20):iii-iv, ix-113. Review.

13.

Progressive nature of aspartylglucosaminuria.

Arvio P, Arvio M.

Acta Paediatr. 2002;91(3):255-7. Review.

PMID:
12022293
14.

[Aspartylglucosaminuria].

Yamaguchi S.

Ryoikibetsu Shokogun Shirizu. 1998;(19 Pt 2):466-8. Review. Japanese. No abstract available.

PMID:
9645112
15.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
16.

ANGIOKERATOMA CORPORIS DIFFUSUM UNIVERSALE: FABRY'S DISEASE; CASE REPORT AND REVIEW OF THE LITERATURE.

WACHTEL HL, MATTEI IR.

Arch Intern Med. 1964 Dec;114:805-11. Review. No abstract available.

PMID:
14211596
17.

Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.

Mignani R, Cagnoli L.

J Nephrol. 2004 May-Jun;17(3):354-63. Review.

PMID:
15365954
18.

[Cardiac manifestation of Fabry's disease: current knowledge].

Palecek T, Lubanda JC, Magage S, Karetová D, Bultas J, Linhart A.

Vnitr Lek. 2004 Nov;50(11):846-51. Review. Czech.

PMID:
15648965
19.

Aspartylglucosaminuria (AGU): protein and gene structure of normal and mutated aspartylglucosaminidase.

Halila R, Ikonen E, Tollersrud O, Syvänen AC, Enomaa N, Peltonen L.

Biochem Med Metab Biol. 1993 Aug;50(1):1-8. Review. No abstract available.

PMID:
8373629
20.

Progressive hearing loss in Fabry's disease: a case report.

Barras FM, Maire R.

Eur Arch Otorhinolaryngol. 2006 Jul;263(7):688-91. Epub 2006 Mar 7. Review.

PMID:
16521018
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk